Michael A. Griffith Appointed to Repligen Board of Directors

Repligen Corporation (NASDAQ:RGEN) today announced that Mr. Michael A. Griffith has been appointed to serve on the Company’s Board of Directors. Mr. Griffith, 53, has extensive leadership experience in the bioprocessing and biopharmaceutical industries, as well as significant commercial and investment banking expertise. Mr. Griffith currently serves as Chief Executive Officer of Laureate Biopharmaceutical Services, Inc. (Laureate Biopharma), a full-service contract manufacturing organization focused on the production and manufacture of biologic drugs for biopharmaceutical customers worldwide.

“Michael’s background in biologics manufacturing is particularly relevant to Repligen, and he also brings valuable financial markets acumen to the Board,” said Walter C. Herlihy, President and Chief Executive Officer of Repligen. “In light of the major commitment that we made to bioprocessing with the December acquisition of Novozymes Biopharma - now Repligen Sweden - we welcome Michael’s insight in helping to guide the integration and expansion of this core business. We value the expertise that Michael offers during this exciting time of Repligen’s transition to a fully integrated and commercially focused company.”

Mr. Griffith has held numerous executive level positions, including his current role since April 2010 as CEO and director of Laureate Biopharma. He is the founder of Aptuit, Inc., a global contract pharmaceutical research, development and manufacturing company, and from 2004 to 2008 served as the company’s CEO. From 1996 to 2000, Mr. Griffith was with ChiRex, Inc., where he initially served as Chief Financial Officer before being named the company’s Chairman and CEO. ChiRex was a Nasdaq-listed pharmaceutical contract development and manufacturing organization specializing in small-molecule drug substance development. Mr. Griffith was part of the team that led the initial public offering for ChiRex, which later sold for $600 million to Rhodia SA, a NYSE-listed, Paris-based specialty chemicals company. Mr. Griffith led the teams that built both Aptuit and ChiRex to become international pharmaceutical supply companies with over 2,700 and 600 employees, respectively. Between 2000 and 2004, he was a consultant to Rhodia and several private equity and pharmaceutical companies. Mr. Griffith for eight years served as Chairman of the Board and Chairman of the Executive Committee at Centrue Financial Corporation and Centrue Bank, a Nasdaq-listed commercial bank. Prior to his involvement in the biopharmaceutical industry, Mr. Griffith worked nearly 15 years as a commercial and investment banker at Bankers Trust and First Boston. He earned a Masters of Management from the Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Science in Business Administration from the University of Kansas.

About Repligen Corporation

Repligen Corporation is a leading supplier of critical biologic products used to manufacture biologic drugs. Repligen also applies its expertise in biologic product development to SecreFlo™, a synthetic hormone being developed as a novel imaging agent for the diagnosis of a variety of pancreatic diseases. In addition, the Company has two central nervous system (CNS) rare disease programs in Phase 1 clinical trials. Repligen’s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested at www.repligen.com.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements regarding future financial performance and position, plans and objectives for future operations, plans and objectives for product development, plans and objectives for regulatory approval, product development, our market share and product sales and other statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to develop and commercialize products and the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; the ability to obtain, and the timing and receipt of, FDA approval for our NDA; our ability to obtain other required regulatory approvals; the success of current and future collaborative or supply relationships; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; the success of our clinical trials; new approaches to the treatment of our targeted diseases; our compliance with all Food and Drug Administration and EMEA regulations; our ability to obtain, maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales capabilities; our volatile stock price; and other risks detailed in Repligen’s annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

Contacts:

Repligen Corporation
Walter C. Herlihy, 781-419-1900
President and Chief Executive Officer
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here